Drug intelligence / Profile preview

EyeLief + EyeLief-SD

Development stage: Preclinical
Lead developer: Re-Vana Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravitreal

Overview

EyeLief + EyeLief-SD is a combination therapy under development by Re-Vana Therapeutics, delivered via a biodegradable sustained-release intravitreal (IVT) implant. The therapy combines EyeLief, which contains the anti-VEGF agent aflibercept, with EyeLief-SD, a bispecific antibody. This combination is designed to provide long-term therapeutic effects for retinal diseases such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) by reducing the frequency of injections. The EyeLief platform uses pre-fabricated implants to ensure controlled drug release over several months. While aflibercept targets vascular endothelial growth factor (VEGF), the specific targets of the bispecific antibody in EyeLief-SD remain undisclosed.

Other names: EyeLief/EyeLief-SD combination

Targets

VEGFB (Vascular endothelial growth factor B)PGF (Placental Growth Factor)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on EyeLief + EyeLief-SD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EyeLief + EyeLief-SD.

Explore the full profile